

Name of the Issuer:	Jupiter Life Line Hospitals Limited	Last updated on	15-Feb-26
<b>1 Type of Issue (IPO / FPO)</b>	IPO		
Source: Prospectus dated September 11, 2023			
<b>2 Issue Size (Rs. Million)*</b>	<b>8,690.76</b>		
- Fresh Issue Size (Rs. Millions)	5,420.01		
- Offer for Sale Component (Rs. Millions)	3,270.75		
* The Company has, in consultation with the BRLMs, undertaken a private placement of 1,673,469 Equity Shares aggregating to ₹ 1,229.99 million ("Pre-IPO Placement"). The size of the Fresh Issue of Equity Shares has been adjusted to ₹1,229.99 million			
*Source: Prospectus dated September 11, 2023			
<b>3 Grade of issue along with name of the rating agency</b>			
<b>Name</b>	Not Applicable		
<b>Grade</b>	Not Applicable		
Source: Prospectus dated September 11, 2023			
<b>4 Subscription Level (Number of times)</b>	<b>65.44*</b>		
*Source: Final post issue report dated September 11, 2023			
*The above figure is after technical rejections, multiple or duplicate Bids and Bids not banked/returned.			
<b>5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges</b>			
<b>Particulars</b>	<b>%</b>		
(i) allotment in the issue**	13.50%		
(ii) at the end of 1st Quarter immediately after the listing (September 30, 2023)*	20.76%		
(iii) at the end of 1st FY (March 31, 2024)*	21.75%		
(iv) at the end of 2nd FY (March 31, 2025)	20.76%		
(v) at the end of 3rd FY (March 31, 2026)*	Not Available		
**As a % of total paid up capital as per prospectus dated September 11, 2023			
*Holding of institutions category as disclosed to Stock Exchanges			
*QIB Holding not disclosed as reporting for the relevant period / fiscal year has not been completed.			
<b>6 Financials of the issuer</b>			
			(In Rs. Millions)
<b>Parameters</b>	<b>1st FY (March 31, 2024)</b>	<b>2nd FY (March 31, 2025)</b>	<b>3rd FY (March 31, 2026)*</b>
Income from Operations	10,695.00	12,615.45	Not Available
Net Profit for the period	1,766.12	1,935.00	Not Available
Paid-up equity share capital	655.66	655.56	Not Available
Reserves excluding revaluation reserves	11,031.73	12906.8	Not Available
*Financials not disclosed as reporting for the relevant fiscal year has not been completed.			
<b>7 Trading Status in the scrip of the issuer</b>			
Company's Equity Shares are listed on both BSE Limited and National Stock Exchange of India Limited			
The Shares have not been suspended or delisted.			
<b>Particulars</b>	<b>Status</b>		
(i) at the end of 1st FY (March 31, 2024)	Frequently traded		
(ii) at the end of 2nd FY (March 31, 2025)	Frequently traded		
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available		
*Trading status not disclosed as the relevant fiscal year has not been completed.			
Source: Stock exchange data.			
<b>8 Change in Directors of issuer from the disclosures in the offer document</b>			
<b>Particulars</b>	<b>Name of the Director</b>	<b>Appointed / Resigned</b>	
(i) at the end of 1st FY (March 31, 2024)	-	-	
(ii) at the end of 2nd FY (March 31, 2025)#	Mr. Amar Manjrekar	Appointed	
	Dr. Ajay Thakker	Reappointed	
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	Not Available	
*Changes in Directors not disclosed as the relevant fiscal year has not been completed.			
# Updated till Feb 15, 2026 from Stock Exchange Announcement			
<b>9 Status of implementation of project/ commencement of commercial production</b>			
(i) as disclosed in the offer document		Not applicable*	
(ii) Actual implementation		Not applicable*	
(iii) Reasons for delay in implementation, if any		Not applicable*	
*The Company did not undertake any project			

**10 Status of utilization of issue proceeds**

(i) As disclosed in the offer document

Particular	Amount to be funded from the Net Proceeds	Estimated Utilisation of Net Proceeds and the Pre-IPO Placement		
		Fiscal 2024	Fiscal 2025	Fiscal 2026
Repayment/pre-payment, in full or part, of borrowings availed from banks by the Company and Material Subsidiary	5,101.55	5,101.55	Not Applicable	-
General Corporate Purpose	11.63	11.63	Not Applicable	-
<b>Total</b>	<b>5,113.18</b>	<b>5,113.18</b>		

Sourced from Prospectus dated September 11, 2023

(ii) Actual utilization

Particular	Actual Utilisation of Net Proceeds and the Pre-IPO Placement		
	Fiscal 2024*	Fiscal 2025#	Fiscal 2026
Repayment/pre-payment, in full or part, of borrowings availed from banks by the Company and Material Subsidiary	5,101.55	Not Applicable	-
General Corporate Purpose	11.63	Not Applicable	-
<b>Total</b>	<b>5,113.18</b>		

\* As per report issued by Monitoring agent dated May 10, 2024 the entire amount is utilised and hence not applicable for 2025

(iii) Reasons for deviation, if any Not Applicable

**11 Comments of monitoring agency**

(a) Comments on use of funds Not Applicable\*

(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document No Deviation\*

(c) Any other reservations expressed by the monitoring agency about the end use of funds Nil\*

\*Report issued by Monitoring agent dated May 10, 2024

**12 Pricing Data**

Issue Price (Rs.): 735.00  
 Designated Stock Exchange: NSE  
 Listing Date: 18-Sep-23

Price parameters	At close of listing day (September 18, 2023)	At close of 30th calendar day from listing day (October 17, 2023) <sup>(1)</sup>	At close of 90th calendar day from listing day (December 16, 2023) <sup>(2)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2024) <sup>(3)</sup>		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange <sup>(6)</sup>	1,075.75	1,045.65	1,150.60	1,192.70	1,653.95	970.00
NIFTY 50 <sup>(6)</sup>	20,133.30	19,811.50	21,456.65	22,462.00	22,526.60	17,312.75
Sectoral Index <sup>(6)</sup>	Not Applicable			Not Applicable		

Price parameters	As at the end of 2nd FY after the listing of the issue			As at the end of 3rd FY after the listing of the issue		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange <sup>(6)</sup>	1,596.55	1,624.15	1,564.95	Not Available	Not Available	Not Available
NIFTY 50 <sup>(6)</sup>	23,519.35	23,649.20	23,649.20	Not Available	Not Available	Not Available
Sectoral Index <sup>(6)</sup>	Not Applicable			Not Applicable		

Source: NSE website

Note:

- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
- (2) 90th calendar day shall be taken as listing date plus 89 calendar days.
- (3) High and Low based on intra day prices
- (4) Pricing data not disclosed as the relevant period/ fiscal year has not completed
- (5) In case of any reporting day falling on a holiday, next trading day prices/values have been disclosed.
- (6) Comparable Sectoral index is not available

## 13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2024)	At the end of 2nd FY (March 31, 2025) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2026) <sup>(2)</sup>
<b>EPS (Basic)</b>				
<b>Issuer:</b>				
Consolidated (Basic)	13.95	28.65	29.47	Not Available
Consolidated (Diluted)	12.95	28.65	29.47	Not Available
<b>Peer Group: (Diluted)</b>				
Apollo Hospitals Enterprise Limited	Basic - 56.97 Diluted - 56.97	Basic - 70.28 Diluted - 70.28	Basic - 90.15 Diluted - 90.15	Not Available
Fortis Healthcare Limited	Basic - 7.80 Diluted - 7.80	Basic - 2.64 Diluted - 2.64	Basic - 0.84 Diluted - 0.84	Not Available
Max Healthcare Institute Limited	Basic - 11.38 Diluted - 11.36	Basic - 7.07 Diluted - 7.05	Basic - 7.21 Diluted - 7.17	Not Available
Narayana Hrudayalaya Limited	Basic - 29.85 Diluted - 29.85	Basic - 20.90 Diluted - 20.90	Basic - 21.23 Diluted - 21.23	Not Available
Global Health Limited	Basic - 12.58 Diluted - 12.57	Basic - 17.80 Diluted - 17.80	Basic - 17.18 Diluted - 17.18	Not Available
Krishna Institute of Medical Sciences Limited	Basic - 42.03 Diluted - 42.03	Basic - 29.41 Diluted - 29.41	Basic - 7.57 Diluted - 7.57	Not Available
<b>Industry Avg:</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>
<b>Price to Earnings Ratio (P/E)</b>				
<b>Issuer:</b>				
Consolidated (Basic)	56.76	41.63	54.18	Not Available
Consolidated (Diluted)	56.76	41.63	54.18	Not Available
<b>Peer Group: (Consolidated)</b>				
Apollo Hospitals Enterprise Limited	Basic - 84.64 Diluted - 84.64	Basic - 91.82 Diluted - 91.82	Basic - 65.79 Diluted - 65.79	Not Available
Fortis Healthcare Limited	Basic - 40.26 Diluted - 40.26	Basic - 162.25 Diluted - 162.25	Basic - 68.07 Diluted - 68.07	Not Available
Max Healthcare Institute Limited	Basic - 45.97 Diluted - 45.97	Basic - 115.21 Diluted - 115.54	Basic - 99.09 Diluted - 99.63	Not Available
Narayana Hrudayalaya Limited	Basic - 33.14 Diluted - 33.14	Basic - 61.89 Diluted - 61.89	Basic - 43.50 Diluted - 43.50	Not Available
Global Health Limited	Basic - 53.70 Diluted - 53.70	Basic - 74.69 Diluted - 74.69	Basic - 67.53 Diluted - 67.53	Not Available
Krishna Institute of Medical Sciences Limited	Basic - 45.09 Diluted - 45.09	Basic - 69.54 Diluted - 69.54	Basic - 67.83 Diluted - 67.83	Not Available
<b>Industry Avg:</b>	<b>50.47</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>
<b>RoNW(%)</b>				
<b>Issuer:</b>				
Consolidated	20.03%	15.11%	14.32%	Not Available
<b>Peer Group: (Consolidated)</b>				
Apollo Hospitals Enterprise Limited	16.40%	13.10%	17.68%	Not Available
Fortis Healthcare Limited	20.90%	2.19%	9.21%	Not Available
Max Healthcare Institute Limited	62.80%	8.95%	11.47%	Not Available
Narayana Hrudayalaya Limited	35.40%	27.36%	38.02%	Not Available
Global Health Limited	16.20%	16.45%	14.24%	Not Available
Krishna Institute of Medical Sciences Limited	25.70%	12.61%	17.64%	Not Available
<b>Industry Avg:</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>
<b>NAV per Equity Share</b>				
<b>Issuer:</b>				
Consolidated	64.39	178.25	206.16	Not Available
<b>Peer Group: (Consolidated)</b>				
Apollo Hospitals Enterprise Limited	378.33	536.28	592.11	Not Available
Fortis Healthcare Limited	46.67	120.37	116.40	Not Available
Max Healthcare Institute Limited	24.14	79.03	96.49	Not Available
Narayana Hrudayalaya Limited	90.5	90.05	101.66	Not Available
Global Health Limited	90.35	108.21	125.88	Not Available
Krishna Institute of Medical Sciences Limited	193.96	233.23	58.76	Not Available
<b>Industry Avg:</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>

(1) Prospectus dated September 11, 2023

(2) Information not provided as the relevant fiscal year has not completed

**Source:**

\* All the financial information for the Company above is sourced from the Restated Summary Statement

\*\*Information for the industry peers mentioned above is on a consolidated basis and is sourced/derived from the respective annual results for the year ended March 31, 2023 of such industry peers available on the website of stock exchange

**Notes:**

1) Earnings per share (Basic) = Restated net profit after tax, available for equity shareholders/Weighted average number of equity shares outstanding during the period/year.

2) Earnings per share (Diluted) = Restated profit for the period/year / Weighted average number of diluted potential equity shares

3) Return on Net Worth (For Jupiter Life Line Hospitals Limited) (%) = Restated net profit after tax / Restated Net Worth at the end of the

4) Return on Net Worth (For listed industry peers) (%) = Profit after tax / Tangible Net Worth.

5) Net Worth means the aggregate value of the paid-up share capital and all reserves created out of the profits, securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of

6) Tangible net worth = Total Net Worth – Intangible assets.

7) Net asset value per share (For Jupiter Life Line Hospitals Limited) (in ₹) = Restated Net Worth at the end of the period/year / Number

8) Net asset value per share (For listed industry peers) = Tangible Net Worth as at end of the period/year / Number of equity shares

9) Operating income = Gross sales + Other related income.

10) P/E is calculated basis closing market price of equity shares from NSE divided by diluted by the diluted earnings per share.

14 Any other material information

Date of disclosure	Announcement
18-Sep-23	Trading Members of the Exchange are hereby informed that effective from September 18, 2023, the equity shares of Jupiter Life Line Hospitals Ltd (Scrip Code: 543980) are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities. For further details please refer to the notice no 20230915- dated September 15, 2023.
20-Sep-23	The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBI Mutual Funds
29-Sep-23	Closure of Trading Window
30-Sep-23	Board Meeting Intimation for Notice Of Board Meeting To Be Held On Friday October 6, 2023 to Consider And Approve The Unaudited Financial Results Along With Limited Review Report Of The Company For The Quarter Ended June 30, 2023 Under Outcome Of The Board Meeting Held On Friday, 6th October 2023
6-Oct-23	Announcement under Regulation 30 (LODR)-Investor Presentation
6-Oct-23	Announcement under Regulation 30 (LODR)-Investor Presentation
6-Oct-23	Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (LODR Regulations) Read With Schedule III Of LODR Regulations And Offer Letter Dated September 11, 2023
8-Oct-23	Newspaper Publication for Unaudited Financial Results( Standalone and Consolidated) for quarter ended 30th June,2023
16-Oct-23	Compliance certificate under Reg. 74(G) of SEBI (DP) Regulations, 2018 for Quarter ended 30th September, 2023
2-Nov-23	Jupiter Life Line Hospitals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023, inter alia, to consider and approve the Un-audited Financial Results along with the Limited Review Report of the Company for the quarter and half year ended September 30, 2023 under Regulation 33 of the SEBI Listing Regulation
10-Nov-23	Board Meeting Outcome For The Quarter And Half Year Ended September 30, 2023
10-Nov-23	Investor Presentation for the quarter and half year ended September 30, 2023
10-Nov-23	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
10-Nov-23	Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements)
12-Nov-23	Announcement under Regulation 30 (LODR)-Newspaper Publication
21-Nov-23	Q2 & H1 FY24 Earnings Conference Call- Transcript
29-Dec-23	INTIMATION OF TRADING WINDOW CLOSURE FOR THE QUATER AND NINE MONTHS ENDED ON 31 DECEMBER, 2023
29-Dec-23	Jupiter Life Line Hospitals Limited-543980-Closure of Trading Window - XBRL
11-Jan-24	Pursuant to Reg 74(G) of SEBI (DP) Regulation we are filing the certificate received from RTA for the quarter ended 31st December, Intimation Under Regulation 30 (5) Of The Securities And Exchange Board Of India ("SEBI") (Listing Obligations And Disclosure Requirements Regulations, 2015
16-Jan-24	Intimation Under Regulation 8 Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015
18-Jan-24	Board Meeting Intimation for To Consider And Approve The Un-Audited Financial Results Along With The Limited Review Report Of Jupiter Life Line Hospitals Limited-543980-Closure of Trading Window - XBRL
1-Feb-24	Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, February 9, 2024
9-Feb-24	Outcome Of The Board Meeting Held On Friday, February 9, 2024
9-Feb-24	Intimation Of Resignation Of Internal Auditor
9-Feb-24	Intimation Of Appointment Of Internal Auditor
9-Feb-24	Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended Dec 31, 2023
9-Feb-24	Announcement under Regulation 30 (LODR)-Investor Presentation
9-Feb-24	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
11-Feb-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Feb-24	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
22-Feb-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Acquired land on lease in Pune.'
27-Mar-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Credit Rating
28-Mar-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
28-Mar-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Closure of Trading Window
6-Apr-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Certificate under Regulation 74(G) of SEBI (Depositories and Registrar) Regulations, 2015
2-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange about Board Meeting to be held on 10-May-2024 to inter-alia
2-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Closure of Trading Window
7-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange about Board Meeting to be held on 10-May-2024 to consider
10-May-24	Dr. Ankit Ajay Thakker has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
10-May-24	Jupiter Life Line Hospitals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024.
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange that Board of Directors at its meeting held on May 10, 2024,
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding 'addition of 75 beds in existing Indore Hospital and 22 beds in Indore Hospital'
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about change in Management - Appointment of Secretarial Auditor
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about change in Management - Appointment of Cost Auditor
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding Change in Director(s) of the company.
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding Change in Director(s) of the company.
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed herewith Final Monitoring Agency Report in respect of utilization of proceeds of Initial Public Offer ( IPO ) for the quarter ended March 31, 2024 issued by CRISIL Ratings
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Investor Presentation
10-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 10-May-2024
10-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
12-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Copy of Newspaper Publication of Financial Results for quarter and year ended on March 31, 2024 in Financial Express and Pudhari Newspaper Marathi
13-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Link of Recording
17-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Transcript of the Q4 & FY24 Results Conference Call
23-May-24	Compliances-Reg.24(A)-Annual Secretarial Compliance

26-Jun-24	Closure of Trading Window
12-Jul-24	Fixation Of Record Date For The Purpose Of Final Dividend For The Financial Year 2023-24
12-Jul-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
12-Jul-24	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15-Jul-24	Reg. 34 (1) Annual Report.
15-Jul-24	Notice Of 22nd AGM To Be Held On August 09, 2024
15-Jul-24	Business Responsibility and Sustainability Reporting (BRSR)
16-Jul-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
1-Aug-24	Intimation Under Regulation 30 Of Securities Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015-Resignation Of Statutory Auditors Of Material Subsidiary
5-Aug-24	Board Meeting Intimation for Board Meeting Intimation For To Consider And Approve The Un-Audited Financial Results Along With The Limited Review Report Of The Company (Standalone And Consolidated) For The Quarter Ended June 30, 2024
9-Aug-24	Board Meeting Outcome for Outcome Of Board Meeting Dated August 09, 2024
9-Aug-24	Unaudited Financial Results Along With Limited Review Report June 30, 2024
9-Aug-24	Announcement under Regulation 30 (LODR)-Change in Management
9-Aug-24	Announcement under Regulation 30 (LODR)-Change in Management
9-Aug-24	Announcement under Regulation 30 (LODR)-Change in Directorate
9-Aug-24	Announcement under Regulation 30 (LODR)-Investor Presentation
9-Aug-24	Shareholder Meeting / Postal Ballot-Outcome of AGM
9-Aug-24	Shareholder Meeting / Postal Ballot-Scrutinizer's Report
11-Aug-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
12-Aug-24	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
14-Aug-24	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
6-Sep-24	Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Statutory Auditor Of Material Subsidiary (JHPPL)
14-Sep-24	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Change In Designation Of Senior Management Personnel Of The Company
25-Sep-24	Closure of Trading Window
26-Sep-24	Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
27-Sep-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
8-Oct-24	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
28-Oct-24	Shareholder Meeting / Postal Ballot-Scrutinizer's Report
29-Oct-24	Board Meeting Intimation for Considering And Approving The Un-Audited Financial Results Along With The Limited Review Report Of The Company (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2024
8-Nov-24	Board Meeting Outcome for Outcome Of Board Meeting Dated November 08, 2024
8-Nov-24	Outcome Of Board Meeting Dated November 08, 2024
8-Nov-24	Announcement under Regulation 30 (LODR)-Investor Presentation
10-Nov-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
10-Nov-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
11-Nov-24	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
14-Nov-24	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
24-Dec-24	Closure of Trading Window
1-Jan-25	Material Update On The Intimation Dated May 10, 2024.
10-Jan-25	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
20-Jan-25	Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -Purchase Of Land At Ghodbundar Mira Road, District Thane
3-Feb-25	Board Meeting Intimation for Considering And Approving The Un-Audited Financial Results Along With The Limited Review Report
3-Feb-25	Announcement under Regulation 30 (LODR)-Credit Rating
7-Feb-25	Board Meeting Outcome for Outcome Of Board Meeting Dated February 07, 2025
7-Feb-25	Outcome Of Board Meeting Dated February 07, 2025
7-Feb-25	Announcement under Regulation 30 (LODR)-Investor Presentation
7-Feb-25	Update On The Land Acquired In Pune Intimation Dated February 22, 2024
7-Feb-25	Integrated Filing (Financial)
7-Feb-25	Intimation Under Regulation 8 Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015
7-Feb-25	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
9-Feb-25	Announcement under Regulation 30 (LODR)-Newspaper Publication
11-Feb-25	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
15-Feb-25	Updates - machine readable copy of the financial results for the period ended December 31, 2024
18-Feb-25	Analysts/Institutional Investor Meet/Con. Call Updates
3-Mar-25	Analysts/Institutional Investor Meet/Con. Call Updates
4-Mar-25	General Updates -- Incorporation of a Subsidiary Company
24-Mar-25	
24-Mar-25	Trading Window closure
25-Mar-25	Jupiter Life Line Hospitals Limited has informed the Exchange regarding Hypothecation Agreement
4-Apr-25	Disclosure under SEBI Takeover Regulations
5-May-25	Board Meeting Intimation - to consider and approve the Yearly Audited Financial results of the Company for the
5-May-25	Analysts/Institutional Investor Meet/Con. Call Updates
9-May-25	Outcome of Board Meeting, Dividend, Appointment of Mr. Sivasis San as Chief Financial Officer of the company
9-May-25	Change in Auditors, Amendment to AOA/MOA of the company, Change in Management
9-May-25	Appointment of Dr. Ankit Thakker as Joint Managing Director of the company w.e.f. July 11, 2025, Appointment
9-May-25	Cessation has approved continuation of Mr. Harshad Purani as President Administration and Head CSR (Senior
9-May-25	Scheme of Amalgamation of Medulla Healthcare Private Limited which is wholly-owned subsidiaries of the
9-May-25	Investor Presentation
11-May-25	Copy of Newspaper Publication in the following newspapers with respect to Audited Financial Results
12-May-25	Analysts/Institutional Investor Meet/Con. Call Updates - Link of Recording
15-May-25	Analysts/Institutional Investor Meet/Con. Call Updates -Transcript
19-May-25	Compliances-Reg.24(A)-Annual Secretarial Compliance
11-Jun-25	Intimation Of Record Date
13-Jun-25	Announcement under Regulation 30 (LODR)-Newspaper Publication
17-Jun-25	Notice Of 23rd Annual General Meeting Scheduled To Be Held On Friday, July 11, 2025
17-Jun-25	Reg. 34 (1) Annual Report.
17-Jun-25	Business Responsibility and Sustainability Reporting (BRSR)
18-Jun-25	Announcement under Regulation 30 (LODR)-Newspaper Publication
18-Jun-25	Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations,
20-Jun-25	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26-06-2025	Closure of Trading Window
11-Jul-25	Shareholder Meeting / Postal Ballot-Outcome of AGM

11-Jul-25	Shareholder Meeting / Postal Ballot-Scrutinizer's Report
15-07-2025	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
25-Jul-25	Board Meeting Intimation for Notice Of The Board Meeting To Be Held On Friday, August 01, 2025
25-Jul-25	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
01-08-2025	Board Meeting Outcome for Outcome Of Board Meeting Dated August 01, 2025
01-08-2025	Outcome Of Board Meeting Dated August 01, 2025
01-08-2025	Announcement under Regulation 30 (LODR)-Investor Presentation
01-08-2025	Intimation Under Regulation 30(5) Of The Listing Regulation
03-08-2025	Announcement under Regulation 30 (LODR)-Newspaper Publication
04-08-2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
6-Aug-25	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
09-08-2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26-08-2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11-Sep-25	Announcement under Regulation 30 (LODR)-Restructuring
25-09-2025	Closure of Trading Window
08-10-2025	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13-Oct-25	Clarification sought from Jupiter Life Line Hospitals Ltd
13-Oct-25	Clarification Regarding The News Article
1-Nov-25	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2-Nov-25	Board Meeting Intimation for Prior Intimation Of The Board Meeting To Be Held On Friday, November 07, 2025
04-11-2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
06-11-2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
07-11-2025	Board Meeting Outcome for Outcome Of Board Meeting Dated November 07, 2025
07-11-2025	Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September
07-11-2025	Announcement under Regulation 30 (LODR)-Investor Presentation
09-11-2025	Announcement under Regulation 30 (LODR)-Newspaper Publication
10-11-2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13-Nov-25	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
18-Nov-25	Announcement under Regulation 30 (LODR)-Restructuring
24-12-2025	Closure of Trading Window
6-Jan-26	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
23-01-2026	Board Meeting Intimation for Prior Intimation Of The Board Meeting To Be Held On Friday, January 30, 2026
23-01-2026	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
30-Jan-26	Board Meeting Outcome for Outcome Of Board Meeting Dated January 30, 2026
30-Jan-26	Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025
30-Jan-26	Commencement Of Operations At Jupiter Hospital, Dombivli, Mumbai Metropolitan Region.
30-Jan-26	Announcement under Regulation 30 (LODR)-Investor Presentation
31-01-2026	Announcement under Regulation 30 (LODR)-Investor Presentation
1-Feb-26	Announcement under Regulation 30 (LODR)-Newspaper Publication
2-Feb-26	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
04-02-2026	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
5-Feb-26	Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Source: [www.bseindia.com](http://www.bseindia.com)

**Note:** The Company would meet Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable.

For further updates and information, please refer to the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and / or [www.nseindia.com](http://www.nseindia.com).

**Disclaimer:**

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE") and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.